The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Subgroup analysis of the DETERMINATION trial: RVD vs. autoSCT in patients with multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the subgroup analysis of the DETERMINATION trial (NCT01208662) evaluating the use of lenalidomide, bortezomib, and dexamethasone versus high-dose treatment with autologous stem cell transplantation (autoSCT) in patients with multiple myeloma. The benefit of autoSCT was observed within all subgroups, however, this benefit was less marked in certain subgroups, including African-Americans. An autoSCT was more necessary for high-risk patients, although this varied between subgroups. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
